Abstract
Although a relatively rare malignancy with a national incidence of 3500-4000 annually, Gastrointestinal Stromal Tumor (GIST) is of significance in the realm of clinical and pharmacological research. GIST exhibits remarkable uniformity in its pathogenesis and ultrastructure as 95% of cases are linked to constitutive activation and overexpression of a membrane tyrosine kinase, c-KIT (CD117). Although previously refractory to any course of action but surgery, GIST heralded a triumph in targeted cancer therapy when administration of a specific first-generation tyrosine-kinase inhibitor Imatinib mesylate (STI571) was shown to inhibit c-Kit and demonstrated a significant increase in patient survival. Over the subsequent decade, GIST has become a paradigm for the potency of Imatinib in adjuvant or neoadjuvant therapy, showcasing the clinical relevance and rapidity of translational research in the field of targeted molecular therapy. Subsequent to demonstrating the efficacy of Imatinib as a therapeutic agent, GIST has also exposed the limitations of current targeted therapies. Within two years, 50% of GISTs develop secondary mutations that allow resistance to Imatinib. However, extensive research regarding both primary and secondary c-KIT mutations has illuminated the mechanisms of Imatinib resistance and has the potential to ameliorate this therapeutic setback. Current research to this end lies in two primary directions: the development of tyrosine kinase inhibitors (some of which also inhibit other oncongenic agents such as PDGFR, bcr-abl, and VEGF) that are either generally more potent than Imatinib or less susceptible to specific mechanisms of resistance; and drugs that target the downstream effectors of the mutant c-KIT kinase, including PKC and mTOR. This paper will systematically review current research on second-generation targeted molecular therapy in the treatment of GIST, and expand upon its value as a model for treatment of other solid organ tumors.
Keywords: Gastrointestinal Stromal Tumor, CD117, c-KIT, targeted therapies, neoadjuvant therapy, adjuvant therapy
Mini-Reviews in Medicinal Chemistry
Title: Gastrointestinal Stromal Tumors: A Paradigm for Therapeutic Options in Solid Organ Tumors
Volume: 10 Issue: 7
Author(s): Caroline Novak and Jose G. Trevino
Affiliation:
Keywords: Gastrointestinal Stromal Tumor, CD117, c-KIT, targeted therapies, neoadjuvant therapy, adjuvant therapy
Abstract: Although a relatively rare malignancy with a national incidence of 3500-4000 annually, Gastrointestinal Stromal Tumor (GIST) is of significance in the realm of clinical and pharmacological research. GIST exhibits remarkable uniformity in its pathogenesis and ultrastructure as 95% of cases are linked to constitutive activation and overexpression of a membrane tyrosine kinase, c-KIT (CD117). Although previously refractory to any course of action but surgery, GIST heralded a triumph in targeted cancer therapy when administration of a specific first-generation tyrosine-kinase inhibitor Imatinib mesylate (STI571) was shown to inhibit c-Kit and demonstrated a significant increase in patient survival. Over the subsequent decade, GIST has become a paradigm for the potency of Imatinib in adjuvant or neoadjuvant therapy, showcasing the clinical relevance and rapidity of translational research in the field of targeted molecular therapy. Subsequent to demonstrating the efficacy of Imatinib as a therapeutic agent, GIST has also exposed the limitations of current targeted therapies. Within two years, 50% of GISTs develop secondary mutations that allow resistance to Imatinib. However, extensive research regarding both primary and secondary c-KIT mutations has illuminated the mechanisms of Imatinib resistance and has the potential to ameliorate this therapeutic setback. Current research to this end lies in two primary directions: the development of tyrosine kinase inhibitors (some of which also inhibit other oncongenic agents such as PDGFR, bcr-abl, and VEGF) that are either generally more potent than Imatinib or less susceptible to specific mechanisms of resistance; and drugs that target the downstream effectors of the mutant c-KIT kinase, including PKC and mTOR. This paper will systematically review current research on second-generation targeted molecular therapy in the treatment of GIST, and expand upon its value as a model for treatment of other solid organ tumors.
Export Options
About this article
Cite this article as:
Novak Caroline and G. Trevino Jose, Gastrointestinal Stromal Tumors: A Paradigm for Therapeutic Options in Solid Organ Tumors, Mini-Reviews in Medicinal Chemistry 2010; 10 (7) . https://dx.doi.org/10.2174/138955710791383974
DOI https://dx.doi.org/10.2174/138955710791383974 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification and Characterization of New Proteins in Podocyte Dysfunction of Membranous Nephropathy by Proteomic Analysis of Renal Biopsy
Current Pharmacogenomics and Personalized Medicine Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Epigenetic Mechanisms Underlying Diet-Sourced Compounds in the Prevention and Treatment of Gastrointestinal Cancer
Anti-Cancer Agents in Medicinal Chemistry Weekly Low-doses with Prolonged Infusion of Gemcitabine /Cisplatin for Multi-treated Metastatic Breast Cancer Patients
Current Cancer Therapy Reviews Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Development of Pin1 Inhibitors and their Potential as Therapeutic Agents
Current Medicinal Chemistry A Review of the Three-Dimensional Cell Culture Technique: Approaches, Advantages and Applications
Current Stem Cell Research & Therapy Melanoma and Epigenetic Treatment: Past and Future
Anti-Cancer Agents in Medicinal Chemistry Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology Novel Insight into the Inflammatory and Cellular Responses Following Experimental Glaucoma Surgery: A Roadmap for Inhibiting Fibrosis
Current Molecular Medicine Recent Clinical Experience with Oncolytic Viruses
Current Pharmaceutical Biotechnology Chemistry and Biology of Cyclic Depsipeptides of Medicinal and Biological Interest
Current Medicinal Chemistry Preclinical Evaluation of New Taxoids
Current Pharmaceutical Design Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Biodistribution of Lipid Nanoparticles: A Comparative Study of Pulmonary versus Intravenous Administration in Rats
Current Radiopharmaceuticals Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma
Current Cancer Drug Targets Targeting the Bombesin/Gastrin-Releasing Peptide Receptor to Treat Sepsis
Recent Patents on Anti-Infective Drug Discovery The Effect of Protein Restriction in the In Vitro Metabolism of Albendazole in Rats
Drug Metabolism Letters